Formulation, Optimization, and Characterization of Repaglinide Loaded Nanocrystal for Diabetes Therapy

Table 4

Measurement of % entrapment efficiency, PDI, particle size, In vitro drug release, and zeta potential.

Sr. number	Dependent variable
	Batch	PDI	In vitro drug release study (%)	Particle size (nm)	Zeta potential (mv)
		(Mean ± SD), = 3	(Mean ± SD), = 3	(Mean ± SD), = 3	(Mean ± SD), = 3
1	NC 1	0.510 ± 0.12	55.38 ± 1.25	386.7 ± 10.88	−22.9 ± 0.48
2	NC 2	0.267 ± 0.06	69.08 ± 0.64	213.5 ± 8.68	−23.4 ± 1.22
3	NC3	0.248 ± 0.04	80.58 ± 1.71	187 ± 5.09	−29.4 ± 1.00
4	NC 4	0.665 ± 0.08	59.64 ± 1.1	743.5 ± 12.16	−16.4 ± 2.43
5	NC 5	0.6 ± 0.1	65.33 ± 1.41	543.4 ± 9.66	−25.8 ± 0.52
6	NC 6	0.570 ± 0.05	78.26 ± 2.08	443.7 ± 7.56	−28 ± 2.56
7	NC 7	0.478 ± 0.07	32.88 ± 0.98	619 ± 10.74	−5.69 ± 0.89
8	NC 8	0.355 ± 0.05	44.69 ± 1.21	509.4 ± 11.56	−7.67 ± 0.78
9	NC 9	0.540 ± 0.14	52.71 ± 1.29	751 ± 14.13	−1.19 ± 1.55